Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.
NewLimit announced its plans and Series C fundraising Tuesday. Founders Fund, the noted Silicon Valley venture capital firm co-founded by Peter Thiel, led the financing, which also included Thrive Capital, Lilly Ventures, and money from tech entrepreneurs Nat Friedman and Daniel Gross. The company is now valued at around $3.1 billion, according to co-founder and CEO Jacob Kimmel.
NewLimit was founded in 2021 by Coinbase CEO and co-founder Brian Armstrong, former GV partner and bioengineer Blake Byers, and Kimmel, a stem cell biologist. The South San Francisco-based startup has been moving rapidly, and grabbing investors’ attention. This is the third time in the past year that the company has announced it has raised money from investors — first, a $130 million Series B round in May 2025, followed by another $45 million in October.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
